Abstract:Objective To explore the effect of pretomanid (PA-824) on rifampicin (RFP)-dependent Mycobacterium tuberculosis infection in mice and its mechanism.Methods Thirty-two male SD mice were randomly divided into RFP treatment group, PA-824 treatment group, combination treatment group and control group, with 8 mice in each group. All mice were challenged with RFP-dependent strains of Mycobacterium tuberculosis to establish an RFP-dependent tuberculosis mouse model. The RFP treatment group was given 65 mg/(kg·d) of RFP, the PA-824 treatment group was given 25 mg/(kg·d) of PA-824, and the combination treatment group was given both the drugs in the above doses. The mice in the control group were given the same amount of normal saline by gavage. After 6 weeks of treatment, the weights of lung and spleen tissues, the organ severity score, the bacterial load of the lung and spleen tissues and the pathological results of lung tissues were observed.Results Compared with the control group, the weights and the bacterial load of lung and spleen were all higher in the RFP treatment group, while the weights of lung and spleen, the organ severity score, and the bacterial load of the lung and spleen in the PA-824 treatment group and the combination treatment group were lower (P < 0.05). Compared with the combination treatment group, the weights of lung and spleen, the organ severity score, and the bacterial load of the lung and spleen in the RFP treatment group and the PA-824 treatment group were increased (P < 0.05). Compared with the RFP treatment group, the weights of lung and spleen, the organ severity score, and the bacterial load of the lung and spleen in the PA-824 treatment group were decreased (P < 0.05).Conclusions PA-824 not only mitigates the RFP dependence for controlling Mycobacterium tuberculosis, but itself also exhibits a great inhibitory effect on RFP-dependent Mycobacterium tuberculosis infection in mice. Meanwhile, it may reduce the extent and severity of the lesions in some way.